Immunisation and preventive measures against mpox in pregnant women and children: A scoping review
Immunisierung und präventive Maßnahmen gegen Mpox bei Schwangeren und Kindern: Scoping-Review
PLOS Global Public Health · 06.11.2026 · 6 (11) · e0007583
DOI: 10.1371/journal.pgph.0007583 ↗Auf einen Blick
Der Review kartierte Evidenz zu Impfstoffen und nichtmedikamentösen Maßnahmen gegen Mpox bei Schwangeren und Kindern. Effektivitätsdaten stammten fast vollständig aus Erwachsenen; spezifische Daten für diese Gruppen fehlten.
Fragestellung
Welche Evidenz gibt es zu Impfung und Prävention gegen Mpox bei Schwangeren und Kindern?
Methode
Scoping-Review; Suche in PubMed, Scopus und Google nach seit 2008 veröffentlichten Arbeiten; letzte Suche am 19. September 2025; Vorgehen nach PRISMA-ScR.
Ergebnisse
48 begutachtete Artikel und 16 Grauliteraturquellen eingeschlossen. Nicht replizierende Drittgenerationsimpfstoffe wurden empfohlen. Wirksamkeit: Einzeldosis 36–86 %, zwei Dosen bis etwa 89 %; keine spezifischen Wirksamkeitsschätzungen für Schwangere oder Kinder.
Einschränkungen
Keine Wirksamkeitsschätzungen spezifisch für Schwangere oder Kinder; keine Meldung zur Impfstoffnutzung nach Trimenon; pädiatrische Daten klein; keine randomisierten Studien in diesen Gruppen.
Schlussfolgerung der Autor:innen
Die Autor:innen sehen Bedarf an prospektiven Sicherheits- und Immunogenitätsstudien in Schwangerschaft und Kindheit, an gerechtem Zugang in LMICs und an angepasster Risikokommunikation.
Kernaussagen
- Wirksamkeitsdaten stammten fast vollständig aus Erwachsenen
- Keine spezifischen Effektivitätsdaten für Schwangere oder Kinder
- Hürden: begrenztes Angebot, Kühlkette, Logistik und Impfskepsis
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Scoping Review in der Zeitschrift PLOS Global Public Health, online erschienen am 06.11.2026. Verfasst von Lamisa Rahman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Promotion and Development Society, Dhaka, Bangladesh. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Mpox (monkeypox) poses disproportionate risks to pregnant women and children, yet evidence on immunisation and prevention in these groups remains limited. This scoping review mapped and synthesised existing evidence on vaccines and non-pharmaceutical preventive measures for mpox in pregnant women and children, to assess reported effectiveness, and to identify implementation barriers and facilitators. Peer-reviewed and Grey literature were searched in PubMed, Scopus, and Google for records published since 2008; databases were last searched on 19 September 2025. Screening and data extraction followed a pre-specified protocol and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework. Key themes included immunisation strategies, preventive measures, effectiveness, barriers, and facilitators. Forty-eight peer-reviewed articles and 16 Grey literature sources were included. Third-generation non-replicating vaccines (MVA-BN/JYNNEOS/Imvanex/IMVAMUNE) were consistently recommended for pregnant women and children because of their favourable safety profiles. Observational and programmatic estimates of vaccine effectiveness (single dose 36–86%; two doses up to approximately 89%) came almost entirely from adults, and no effectiveness estimate specific to pregnant women or children was identified. No source reported vaccine use by trimester, and paediatric data were limited to small studies. Ring vaccination and post-exposure prophylaxis (PEP) were supported mainly by adult data. Major barriers included limited vaccine supply and cold-chain and logistical constraints in low- and middle-income countries (LMICs), vaccine hesitancy driven by safety concerns, particularly in pregnancy, and the absence of randomised trials in pregnant women and children. Few sources were centred on Africa or other LMICs. Facilitators included international coordination, targeted surveillance, flexible delivery strategies such as intradermal dosing, and integration with maternal and child health services. Priorities include prospective safety and immunogenicity studies in pregnancy and childhood, equitable vaccine access in LMICs, and tailored risk communication to address hesitancy.
Autor:innen und Institutionen
- Public Health Promotion and Development Society, Dhaka, Bangladesh.
- BRAC James P Grant School of Public Health, BRAC University, Dhaka, Bangladesh.
- National Tuberculosis Control Programme, Directorate General of Health Services, Dhaka, Bangladesh.
- Department of Laboratory Medicine, Continental Hospital PLC, Dhaka, Bangladesh.
- Projahnmo Research Foundation, Dhaka, Bangladesh.
- Department of Public Health, North South University, Dhaka, Bangladesh.
ORCID-Profile: Lamisa Rahman, Fahima Nasrin Eva, A K M Ahsanuzzaman, Anindita Tabassum
Zitieren
APA
Rahman, L., Eva, F. N., Ahsanuzzaman, A. K. M., Monami, S., Tabassum, A., Nabi, M. H., & Hawlader, M. D. H. (2026). Immunisation and preventive measures against mpox in pregnant women and children: A scoping review. PLOS Global Public Health, 6(11), e0007583. https://doi.org/10.1371/journal.pgph.0007583
Vancouver
Rahman L, Eva FN, Ahsanuzzaman AKM, Monami S, Tabassum A, Nabi MH, et al. Immunisation and preventive measures against mpox in pregnant women and children: A scoping review. PLOS Global Public Health. 2026;6(11):e0007583. doi:10.1371/journal.pgph.0007583
BibTeX
@article{Rahman2026,
author = {Rahman, Lamisa and Eva, Fahima Nasrin and Ahsanuzzaman, A K M and Monami, Sadia and Tabassum, Anindita and Nabi, Mohammad Hayatun and Hawlader, Mohammad Delwer Hossain},
title = {Immunisation and preventive measures against mpox in pregnant women and children: A scoping review},
journal = {PLOS Global Public Health},
year = {2026},
volume = {6},
number = {11},
pages = {e0007583},
doi = {10.1371/journal.pgph.0007583}
}
EUVIMED